{"meshTags":["Humans","Melanoma","Dose Fractionation","Pneumonectomy","Protein Kinase Inhibitors","Lung Neoplasms","Male","Skin Neoplasms","Proto-Oncogene Proteins B-raf","Adult","Oximes","Imidazoles"],"meshMinor":["Humans","Melanoma","Dose Fractionation","Pneumonectomy","Protein Kinase Inhibitors","Lung Neoplasms","Male","Skin Neoplasms","Proto-Oncogene Proteins B-raf","Adult","Oximes","Imidazoles"],"genes":["BRAF","V600E BRAF","BRAF","GSK2118436"],"organisms":["9606","9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"The authors herein report the case of a 32-year-old man with advancing metastatic malignant melanoma, who has progressed through all previous lines of therapy, presenting with ongoing respiratory tract symptoms of exertional shortness of breath and cough. CT restaging confirmed clinical findings of deteriorating pulmonary disease; histological review revealed V600E BRAF mutation. He was started on targeted biological therapy with BRAF inhibitor GSK2118436, and is having a good clinical and radiological response without significant lasting toxicity.","title":"Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma.","pubmedId":"22744255"}